These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 10901822)

  • 1. AT1 receptor blockers--cost-effectiveness within the South African context.
    Anderson AN; Wessels F; Moodley I; Kropman K
    S Afr Med J; 2000 May; 90(5):494-8. PubMed ID: 10901822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
    Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
    Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
    Petrella R; Michailidis P
    Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II antagonists in the treatment of hypertension-effective and efficient?
    Müller-Nordhorn J; Willich SN
    Herz; 2003 Dec; 28(8):733-7. PubMed ID: 14689108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
    Cice G; Ferrara L; Tagliamonte E; Russo PE; Di Benedetto A; Iacono A
    Cardiologia; 1999 Dec; 44(12):1071-6. PubMed ID: 10687258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of valsartan versus losartan and the effect of switching.
    Baker TM; Goh J; Johnston A; Falvey H; Brede Y; Brown RE
    J Med Econ; 2012; 15(2):253-60. PubMed ID: 22084957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: results from the Study on COgnition and Prognosis in the Elderly.
    Lundkvist J; Ekman M; Kartman B; Carlsson J; Jönsson L; Lithell H
    J Hum Hypertens; 2005 Jul; 19(7):569-76. PubMed ID: 15800664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan.
    Simons WR
    Pharmacoeconomics; 2003; 21(1):61-74. PubMed ID: 12484804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of hypertension treatment in Sweden: an analysis of the criteria for intervention and the choice of drug treatment.
    Johannesson M
    J Hum Hypertens; 1996 Feb; 10 Suppl 2():S23-6. PubMed ID: 8868040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redefining efficacy of antihypertensive therapies beyond blood pressure reduction--the role of angiotensin II antagonists.
    Conlin PR
    Int J Clin Pract; 2005 Feb; 59(2):214-24. PubMed ID: 15854200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sympatho-inhibitory properties of various AT1 receptor antagonists.
    Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
    J Hypertens Suppl; 2002 Jun; 20(5):S3-11. PubMed ID: 12184061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group.
    Gradman AH; Lewin A; Bowling BT; Tonkon M; Deedwania PC; Kezer AE; Hardison JD; Cushing DJ; Michelson EL
    Heart Dis; 1999; 1(2):52-7. PubMed ID: 11720604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological properties of angiotensin II receptor antagonists.
    Timmermans PB
    Can J Cardiol; 1999 Nov; 15 Suppl F():26F-8F. PubMed ID: 10579749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension.
    Miller LA; Wade R; Dai D; Cziraky MJ; Ramaswamy K; Panjabi S
    Curr Med Res Opin; 2010 Jun; 26(6):1307-20. PubMed ID: 20370377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P; Reismann J; Pohlmeyer H; Düsing R
    Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost-effectiveness of treatment of high blood pressure with losartan in Denmark].
    Keiding H; Hildebrandt P; Burke T; Carides GW
    Ugeskr Laeger; 2006 Oct; 168(42):3623-6. PubMed ID: 17069726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
    Sever PS
    Blood Press Suppl; 2000; 1():19-22. PubMed ID: 11059631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-benefit effectiveness of angiotensin-II receptor blockers in patients with uncomplicated hypertension: A comparative analysis.
    Mazza A; Sacco AP; Townsend DM; Bregola G; Contatto E; Cappello I; Schiavon L; Ramazzina E; Rubello D
    Biomed Pharmacother; 2017 Jun; 90():665-669. PubMed ID: 28415046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.